Core Viewpoint - The company, Lisheng Pharmaceutical, announced that its Vice President, Guo Xiaoyan, holds 114,800 shares, accounting for 0.0446% of the total share capital, and plans to reduce holdings by up to 11,200 shares within three months after the announcement [1] Summary by Categories Shareholding Information - Guo Xiaoyan's current shareholding is 114,800 shares, which represents 0.0446% of the total share capital [1] - After excluding repurchased shares, the shareholding percentage is 0.0448% [1] Reduction Plan - The planned reduction involves selling up to 11,200 shares, which constitutes 0.0044% of the total share capital after excluding repurchased shares [1] - The shares to be sold are sourced from the 2022 restricted stock incentive plan [1]

Core Viewpoint - Tianjin Development (00882.HK) announced the signing of the eleventh wealth management agreement with Xingyin Wealth Management and Industrial Bank, involving a principal amount of RMB 30 million for subscribing to another fixed-income investment product [1] Group 1 - The agreement was established on November 19, 2025, indicating a future investment strategy [1] - The investment amount of RMB 30 million is approximately USD 4.2 million, reflecting the company's commitment to diversifying its investment portfolio [1]

Core Viewpoint - Tianjin Development (00882) has announced an investment of RMB 30 million (approximately HKD 32.82 million) in a fixed-income investment product through its indirect non-wholly owned subsidiary, Lifescience Pharmaceutical, in collaboration with Industrial Bank and its wealth management division [1] Group 1 - The investment agreement is the eleventh of its kind between Lifescience Pharmaceutical and Industrial Bank [1] - The transaction is set to take place on November 19, 2025 [1]

Core Viewpoint - Tianjin Development (00882) announced a new investment agreement involving its indirect non-wholly owned subsidiary, Lifesun Pharmaceutical (002393), which will invest in a fixed-income product through a financial agreement with Xingyin Wealth Management and Industrial Bank [1] Group 1 - Lifesun Pharmaceutical has entered into its eleventh financial agreement with Industrial Bank, committing a principal amount of RMB 30 million, equivalent to approximately HKD 32.82 million [1]

Core Viewpoint - Tianjin Development (00882.HK) announced the signing of the eleventh wealth management agreement with Xingyin Wealth Management and Industrial Bank, involving an investment of RMB 30 million in a fixed-income investment product, set to mature on November 19, 2025 [1] Group 1 - The investment amount is RMB 30 million, which is approximately USD 4.2 million [1] - The agreement is part of a series of wealth management agreements, indicating a continued strategy of diversifying investment channels [1] - The maturity date for this investment product is set for November 19, 2025, suggesting a medium-term investment horizon [1]

关于使用闲置自有资金进行现金管理的进展公告 本公司及董事会全体成员保证信息披露的内容真实、准确和完整，没有虚假记载、 误导性陈述或重大遗漏。 证券代码：002393 证券简称：力生制药 公告编号：2025-074 天津力生制药股份有限公司 天津力生制药股份有限公司（以下简称"公司"）于2025年3月19日召开第七届董事会第 五十次会议、2025年4月11日召开2024年度股东大会，审议通过了《关于公司2025年使用 闲置自有资金进行现金管理额度的议案》，同意公司使用额度不超过人民币10亿元闲置自 有资金购买安全性高、流动性好、主要大型商业银行或证券机构发行的短期理财产品，包 括但不限于通过银行、证券等专业理财机构购买的理财产品，期限不超过股东大会批准之 日起12个月，在上述额度及期限范围内资金滚动使用。具体内容详见公司于2025年3月21 日在巨潮资讯网(www.cninfo.com.cn）披露的《关于公司2025年使用闲置自有资金进行现 金管理额度的公告》（公告编号：2025-024）。 一、本次进行现金管理购买理财产品情况 2.理财产品发行人提示了产品包括但不限于信用风险、利率风险、市场风险、流动性风 险 ...

2016-2025年1-9月化学原料和化学制品制造业企业数统计图 数据来源：国家统计局，智研咨询整理 知前沿，问智研。智研咨询是中国一流产业咨询机构，十数年持续深耕产业研究领域，提供深度产业研 究报告、商业计划书、可行性研究报告及定制服务等一站式产业咨询服务。专业的角度、品质化的服 务、敏锐的市场洞察力，专注于提供完善的产业解决方案，为您的投资决策赋能。 上市公司：海南海药（000566），东北制药（000597），亚太实业（000691），通化金马（000766）， 北大医药（000788），力生制药（002393），海普瑞（002399），科伦药业（002422），杭氧股份 （002430），长江健康（002435），誉衡药业（002437），华软科技（002453） 相关报告：智研咨询发布的《2025-2031年中国基础化学原料行业市场供需态势及投资前景研判报告》 2025年1-9月，化学原料和化学制品制造业企业数（以下数据涉及的企业，均为规模以上工业企业，从 2011年起，规模以上工业企业起点标准由原来的年主营业务收入500万元提高到年主营业务收入2000万 元）为26965个，和上年同期相比，增加了 ...

Group 1 - The core viewpoint of the article highlights the growth of industrial enterprises in Tianjin, with a total of 6,270 enterprises reported as of January to September 2025, marking an increase of 223 enterprises compared to the same period last year, representing a year-on-year growth of 3.69% [1][1][1] Group 2 - The report indicates that the number of industrial enterprises in Tianjin accounted for 1.2% of the national total [1][1][1] - The data referenced in the article is sourced from the National Bureau of Statistics and organized by Zhiyan Consulting [1][1][1] - Zhiyan Consulting is recognized as a leading industry consulting firm in China, specializing in in-depth industry research reports, business plans, feasibility studies, and customized services [1][1][1]

Group 1 - The company held its first meeting of the eighth board of directors on November 13, 2025, with all nine directors present, complying with legal and regulatory requirements [2][3][4] - Zhang Ping was elected as the chairman of the eighth board of directors, with his term starting from the date of the meeting [3][4] - The board established several specialized committees, including the Strategy and Development Committee, Nomination Committee, Compensation and Assessment Committee, and Audit Committee [5][6] Group 2 - The board approved the appointment of Wang Fujun as the general manager, with his term also starting from the date of the meeting [6][7] - Three vice general managers were appointed: Long Changfeng, Liang Jiankang, and Guo Xiaoyan, with their terms aligned with the board's term [7][8] - Wang Jiaying was appointed as the financial director, and Ma Feifei was appointed as the board secretary, both with terms starting from the meeting date [8][9] Group 3 - The board approved the appointment of Zhang Guiling as the head of the Audit and Compliance Department and Liu Zilong as the securities representative, with their terms also starting from the meeting date [10][11] - The board discussed the achievement of the first unlock condition for the 2022 stock incentive plan, allowing 14 individuals to unlock a total of 112,728 shares, representing approximately 0.0438% of the company's total shares [21][34] Group 4 - The eighth board of directors consists of nine members, including five non-independent directors and three independent directors, ensuring compliance with regulatory requirements regarding board composition [39][40] - The company confirmed that all appointed members and directors meet the qualifications and have no disqualifying conditions as per relevant laws and regulations [45][46][47][48][49][50]

Core Points - The company, Lisheng Pharmaceutical, announced the appointment of Ms. Ma Feifei as the secretary of the board of directors [1] Group 1 - The board of directors of Lisheng Pharmaceutical approved the hiring of Ms. Ma Feifei [1]